Seminar: Dr. Michael Wagner

On 8 April 2019 at 10:15 in Auditorium 9 Dr. Michael Wagner, Direktor, Sanofi-Aventis, Germany, will give a talk titled "Design and Development Aspects of Next Generation GLP-1 Receptor Agonists for the Treatment of Diabesity."

Therapeutic peptides, such as GLP-1R agonists, are of utmost importance for the treatment of type 2 diabetes and obesity. Whereas first generation peptidic GLP-1R agonists are suitable for once or twice daily dosing, a huge effort has been undertaken by various groups in pharmaceutical industry and academia to develop long lasting GLP-1R agonists for once weekly dosing or even beyond. To further improve the efficacy of GLP-1R agonists, so called GLP-1R Co-agonists, e.g. GLP-1/Glucagonor GLP-1/GIP Co-agonists, have been studied, which show promising results in early clinical trials but are waiting for confirmation in late-stage development. In the lecture I will discuss some general aspects in the design and development of these next generation GLP-1R agonists using selected case studies.

The seminar is hosted by Knud J. Jensen